191 related articles for article (PubMed ID: 24118909)
21. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects.
de la Peña A; Yeo KP; Linnebjerg H; Catton E; Reddy S; Brown-Augsburger P; Morrow L; Ignaut DA
J Diabetes Sci Technol; 2015 Jul; 9(4):824-30. PubMed ID: 25697717
[TBL] [Abstract][Full Text] [Related]
23. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
Heise T; Korsatko S; Nosek L; Coester HV; Deller S; Roepstorff C; Segel S; Kapur R; Haahr H; Hompesch M
J Diabetes; 2016 Jan; 8(1):132-8. PubMed ID: 25581159
[TBL] [Abstract][Full Text] [Related]
24. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
[TBL] [Abstract][Full Text] [Related]
25. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
[TBL] [Abstract][Full Text] [Related]
26. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
[TBL] [Abstract][Full Text] [Related]
27. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
29. Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.
Tiffner K; Boulgaropoulos B; Höfferer C; Birngruber T; Porksen N; Linnebjerg H; Garhyan P; Lam ECQ; Knadler MP; Pieber TR; Sinner F
Diabetes Technol Ther; 2017 May; 19(5):305-314. PubMed ID: 28328234
[TBL] [Abstract][Full Text] [Related]
30. PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.
Caparrotta TM; Evans M
Diabetes Obes Metab; 2014 May; 16(5):388-95. PubMed ID: 23941279
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study.
Farcasiu E; Ivanyi T; Mozejko-Pastewka B; Birkus Z; Csog J; Kowalska I; Coetzer TF; Bulgurlu S; Schinzel B; Kiljanski J
Clin Ther; 2011 Nov; 33(11):1682-93. PubMed ID: 22036246
[TBL] [Abstract][Full Text] [Related]
32. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
[TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
[TBL] [Abstract][Full Text] [Related]
35. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
36. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
Roach P; Malone JK
Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
[TBL] [Abstract][Full Text] [Related]
37. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.
Garg S; Dreyer M; Jinnouchi H; Mou J; Qu Y; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():25-33. PubMed ID: 27393697
[TBL] [Abstract][Full Text] [Related]
38. Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
Rosenstock J; Marre M; Qu Y; Zhang S; Bastyr EJ; Prince MJ; Chang AM
Diabetes Obes Metab; 2016 Nov; 18(11):1093-1097. PubMed ID: 27484021
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
[TBL] [Abstract][Full Text] [Related]
40. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Morrow LA; Leonsson-Zachrisson M; Ericsson H; Wollbratt M; Knutsson M; Hompesch M; Norjavaara E
Diabetes Obes Metab; 2012 Dec; 14(12):1114-22. PubMed ID: 22775976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
